

#### **Company Contact:**

Dror David, Chief Financial Officer Nova Measuring Instruments Ltd.

Tel: +972-73-229-5760

E-mail: <a href="mailto:info@novameasuring.com">info@novameasuring.com</a>

www.novameasuring.com

#### **Investor Relations Contacts:**

Hayden/ MS-IR LLC Miri Segal

Tel: +917-607-8654

E-mail: msegal@ms-ir.com

Or

**Brett Maas** 

Tel: +646-536-7331

E-mail: brett@haydenir.com

### **Company Press Release**

### **Nova Reports Record Fourth Quarter and Full Year 2016 Results**

Record Full-Year Revenue of \$163.9 Million Full-Year GAAP Net Income of \$9.6 Million Record Full-Year Non-GAAP Net Income of \$30.3 Million

Rehovot, Israel, February 14, 2017 - Nova Measuring Instruments (Nasdaq: NVMI), a leading innovator and a key provider of metrology solutions for advanced process control used in semiconductor manufacturing, today reported record financial results for the fourth quarter and full year 2016, the periods ended December 31, 2016.

#### Fourth Quarter 2016 Highlights:

- Record quarterly revenue of \$50.2 million, up 14% sequentially and 25% year-overyear, significantly exceeding guidance of \$42 to \$46 million and as preannounced on January 26, 2017
- GAAP net income of \$8.4 million, or \$0.30 per diluted share, up 58% year-over-year on a per-share basis, exceeding guidance of \$0.23 to \$0.29 per share
- Non-GAAP net income of \$11.7 million, or \$0.42 per diluted share, up 24% sequentially and 121% year-over-year on a per-share basis, exceeding guidance of \$0.31 to \$0.40 per share
- Received over \$10 million in XPS orders from multiple foundry customers
- Received multiple orders from leading 3D-NAND manufacturers

#### Full Year 2016 Highlights:

- Record full-year revenue of \$163.9 million, up 10% year-over-year
- GAAP net income of \$9.6 million, or \$0.35 per diluted share, including non-recurring expense of \$12.9 million related to royalty payment to the Israeli Office of the Chief Scientist
- Record non-GAAP net income of \$30.3 million, or \$1.10 per diluted share, up 44% year-over-year on a per-share basis
- Diversified customer mix yielded four customers contributing more than 10% each to the annual product revenues

	GAAP	Results (\$K)			
	Q4 2016	Q3 2016	Q4 2015	FY 2016	FY 2015
Revenues	\$50,212	\$44,060	\$40,022	\$163,903	\$148,514
Net Income (Loss)	\$8,364	\$(4,778)	\$5,161	\$9,644	\$15,725
Earnings (Loss) per Diluted Share	\$0.30	\$(0.18)	\$0.19	\$0.35	\$0.57
	NON-GA	AP Results (\$I	<)		
	Q4 2016	Q3 2016	Q4 2015	FY 2016	FY 2015
Net Income	\$11,719	\$9,449	\$5,278	\$30,321	\$21,030
Earnings per Diluted Share	\$0.42	\$0.34	\$0.19	\$1.10	\$0.76

A reconciliation between GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this release. Non-GAAP results exclude amortization of acquired intangible assets, net adjustments of deferred tax assets, stock-based compensation expenses, acquisition related expenses, expense related to royalty buyout agreement with the Office of the Chief Scientist and inventory write-off.

### **Management Comments**

"The fourth quarter was an outstanding conclusion to another record year, demonstrating our ability to execute our growth plans effectively while improving our customer diversification and operational model," commented Eitan Oppenhaim, President and Chief Executive Officer of Nova. "We believe that the strong end to 2016 sets us on course for another growth year in 2017, bolstered by growing demand for our entire product portfolio, combining dimensions and materials metrology solutions. The strength of our business, as evidenced by our strong guidance for the first quarter, will continue into 2017 as we continue to secure wins from multiple customers in various industry segments."

Mr. Oppenhaim continued, "Nova's broad offering, which is embraced by our diversified customer base, allows us today to address a wider range of challenges that generate more opportunities for us to grow in 2017. During our continued growth, we have leveraged our proven business model to drive record profits, as evidenced by the significant increase in full-year non-GAAP net income. We expect to continue to benefit from our efficient business model in the coming years, leading to continued profitable growth."

#### 2017 First Quarter Financial Outlook

Management provided an outlook for the first quarter, the period ending March 31, 2017. Based on current estimates, management expects:

- \$50 million to \$54 million in revenue
- \$0.31 to \$0.39 in diluted GAAP EPS
- \$0.37 to \$0.45 in diluted non-GAAP EPS

#### 2016 Fourth Quarter Results

Total revenues for the fourth quarter of 2016 were \$50.2 million, in line with the results announced on January 26, 2017. Sequentially, this represented an increase of 14% compared to the third quarter of 2016, and an increase of 25% relative to the fourth quarter of 2015.

Gross margin for the fourth quarter of 2016 was 56%, compared sequentially with gross margin of 22% in the third quarter of 2016 (which included a non-recurring expense related to royalty buyout agreement) and compared with gross margin of 52% in the fourth quarter of 2015.

Operating expenses in the fourth quarter of 2016 were \$17.4 million. This is compared with \$16.6 million in the third quarter of 2016 and compared with \$17.3 million in the fourth quarter of 2015.

On a GAAP basis, the company reported net income of \$8.4 million, or \$0.30 per diluted share, in the fourth quarter of 2016. This is compared with a net loss of \$4.8 million, or \$0.18 per diluted share, in the third quarter of 2016. The company reported net income of \$5.2 million, or \$0.19 per diluted share, in the fourth quarter of 2015.

On a non-GAAP basis, which excludes amortization of acquired intangible assets, net adjustments of deferred tax assets and stock-based compensation expenses, the company reported net income of \$11.7 million, or \$0.42 per diluted share, in the fourth quarter of 2016. This is compared with net income of \$9.4 million, or \$0.34 per diluted share, in the third quarter of 2016, and compared with net income of \$5.3 million, or \$0.19 per diluted share, in the fourth quarter of 2015.

Cash utilization in the fourth quarter was higher than normal mainly due to the timing of shipments during the quarter, and management expects the first quarter of 2017 to include higher than normal cash generation.

#### 2016 Full Year Results

Total revenues for 2016 were \$163.9 million, an increase of 10% compared to total revenues of \$148.5 million for 2015.

Gross margin in 2016 was 46%, and included \$12.9 million of non-recurring expense related to royalty buyout agreement. This is compared with gross margin of 52% in 2015.

Operating expenses in 2016 were \$65.1 million, compared with operating expenses of \$65.5 million in 2015.

On a GAAP basis, which included \$12.9 million of expense related to a royalty buyout agreement with the Office of the Chief Scientist, the company reported net income of \$9.6 million, or \$0.35 per diluted share, in 2016. This is compared with a net income of \$15.7 million, or \$0.57 per diluted share, in 2015.

On a non-GAAP basis, which excludes amortization of acquired intangible assets, net adjustments of deferred tax assets, stock-based compensation expenses, expense related to a royalty buyout agreement with the Office of the Chief Scientist and inventory write-off, the company reported net income of \$30.3 million, or \$1.10 per diluted share, in 2016. This is compared with net income of \$21.0 million, or \$0.76 per diluted share, in 2015.

Total cash reserves at the end of 2016 were \$91.7 million, compared to \$97.8 million at the end of 2015.

#### **Conference Call Information**

Nova will host a conference call today, February 14, 2017, at 9 a.m. Eastern Time, to discuss the financial results and future outlook. To attend the conference call, please dial one of the following teleconferencing numbers. Please begin by placing your calls five minutes before the conference call commences. If you are unable to connect using the toll-free numbers, please try the international dial-in number.

U.S. Dial-in Number: 1-888-244-2417 ISRAEL Dial-in Number: 1 80 925 8350 INTERNATIONAL Dial-in Number: 1-913-312-0966

At:

9 a.m. Eastern Time 6 a.m. Pacific Time 4 p.m. Israeli Time

#### Please reference conference ID 3628025

The conference call will also be webcast live from a link on Nova's website at <a href="http://ir.novameasuring.com">http://ir.novameasuring.com</a>. For those unable to participate in the conference call, there will be a replay available from a link on Nova's website at <a href="http://ir.novameasuring.com">http://ir.novameasuring.com</a>.

**About Nova: Nova Measuring Instruments** delivers continuous innovation by providing advanced metrology solutions for the semiconductor manufacturing industry. Deployed with the world's largest integrated-circuit manufacturers, Nova's products deliver state-of-the-art, high-performance metrology solutions for effective process control throughout the semiconductor fabrication lifecycle. Nova's product portfolio, which combines high-precision hardware and cutting-edge software, supports the development and production of the most advanced devices in today's high-end semiconductor market. Nova's technical innovation and market leadership enable customers to improve process performance, enhance products' yields and accelerate time to market. Nova acts as a partner to semiconductor manufacturers from its offices around the world. Additional information may be found at <a href="https://www.novameasuring.com">www.novameasuring.com</a>.

Nova is traded on the NASDAQ & TASE under the symbol NVMI.

This press release provides financial measures that exclude charges for amortization of acquired intangible assets, net adjustment of deferred tax assets, stock-based compensation expenses, acquisition related expenses, expense related to royalty buyout agreement with the Office of the Chief Scientist and inventory write-off and are therefore not calculated in accordance with generally accepted accounting principles (GAAP). Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding Nova's performance because they reflect our operational results and enhances management's and investors' ability to evaluate Nova's performance before charges or benefits considered by management to be outside Nova's ongoing operating results. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management believes that it is in the best interest of its investors to provide financial information that will facilitate comparison of both historical and future results and allows greater transparency to supplemental information used by management in its financial and operational decision making. A reconciliation of each GAAP to non-GAAP financial measure discussed in this press release is contained in the accompanying financial tables.

This press release contains forward-looking statements within the meaning of safe harbor provisions of the Private Securities Litigation Reform Act of 1995 relating to future events or our future performance, such as statements regarding, but are not limited to, anticipated growth opportunities and projections about our business and its future revenues, expenses and profitability. Forwardlooking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in those forward looking statements. Factors that may affect our results, performance, circumstances or achievements include, but are not limited to, the following: our dependency on three product lines; our dependency on a small number of large customers and small number of suppliers; the highly cyclical and competitive nature of the markets we target and we operate in; our inability to reduce spending during a slowdown in the semiconductor industry, our ability to respond effectively on a timely basis to rapid technological changes; our ability to recognize the benefits of ReVera acquisition and risks that the acquisition may disrupt current plans and operations and impact relationships with customers, distributors and suppliers; our dependency on PEMs; risks related to exclusivity obligations and non-limited liability that may be included in our commercial agreements and arrangements; our ability to retain our competitive position despite the ongoing consolidation in our industry; risks related to our dependence on our manufacturing facilities; risks related to changes in our order backlog; risks related to the worldwide financial instabilities; risks related to our intellectual property; new product offerings from our competitors; unanticipated manufacturing or supply problems; risks related to government programs we participate in; risks related to taxation; changes in customer demand for our products; risks related to currency fluctuations, risks related to acquisitions we may pursue and risks related to our operations in Israel. We cannot guarantee future results, levels of activity, performance or achievements. The matters discussed in this press release also involve risks and uncertainties summarized under the heading "Risk Factors" in Nova's Annual Report on Form 20-F for the year ended December 31, 2015 filed with the Securities and Exchange Commission on February 29, 2016. These factors are updated from time to time through the filing of reports and registration statements with the Securities and Exchange Commission. Nova Measuring Instruments Ltd. does not assume any obligation to update the forward-looking information contained in this press release.

(Tables to Follow)

### NOVA MEASURING INSTRUMENTS LTD. CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands) - (Unaudited)

	As of December 31,		
ASSETS	2016	2015	
Current assets			
Cash and cash equivalents	20,406	27,733	
Short-term interest-bearing bank deposits	70,546	69,298	
Trade accounts receivable	42,626	19,046	
Inventories	29,260	27,683	
Deferred tax assets	-	3,540	
Other current assets	5,068	2,888	
Total current assets	167,906	150,188	
Long-term assets			
Long-term interest-bearing bank deposits	750	750	
Deferred tax assets	3,020	5,735	
Severance pay funds	1,425	1,514	
Property and equipment, net	10,017	11,062	
Identifiable intangible assets, net	15,361	17,906	
Goodwill	20,114	20,114	
Total long-term assets	50,687	57,081	
Total assets	218,593	207,269	
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities			
Trade accounts payable	16,501	14,378	
Deferred revenues	4,072	5,828	
Deferred tax liabilities	-	956	
Other current liabilities	18,461	15,996	
Total current liabilities	39,034	37,158	
Long-term liabilities			
Deferred tax liabilities	1,094	5,760	
Liability for employee severance pay	2,418	2,469	
Other long-term liabilities	1,330	822	
Total long-term liabilities	4,842	9,051	
Shareholders' equity	174,717	161,060	
Total liabilities and shareholders' equity	218,593	207,269	

# NOVA MEASURING INSTRUMENTS LTD. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. dollars in thousands, except per share data) - (Unaudited)

	Three months ended December 31,		Year ended December 31,	
	2016	2015	2016	2015
Revenues:				
Products	39,806	30,581	122,439	111,178
Services	10,406	9,441	41,464	37,336
Total revenues	50,212	40,022	163,903	148,514
Cost of revenues:				
Products	15,497	12,593	48,577	47,185
Services	6,557	5,524	25,282	20,743
Expense related to royalty buyout agreement				
with the Office of the Chief Scientist	-	-	12,875	-
Inventory write-off	-	-	1,889	-
Amortization of acquired intangible assets in cost of products	_	1,051	_	3,506
Total cost of revenues	22.054		99.622	
- Total cost of levelides	22,054	19,168	88,623	71,434
Gross profit	28,158	20,854	75,280	77,080
Operating expenses:				
Research and development expenses, net	9,225	10,826	34,998	39,703
Sales and marketing expenses	5,814	4,474	20,736	15,768
General and administration expenses	1,702	1,606	6,835	5,856
Acquisition related expenses	-	-	-	2,655
Amortization of acquired intangible assets	636	378	2,545	1,517
Total operating expenses	17,377	17,284	65,114	65,499
Operating income	10,781	3,570	10,166	11,581
Financing income, net	190	184	1,216	643
Income before tax on income	10,971	3,754	11,382	12,224
Income tax expenses (benefit)	2,607	(1,407)	1,738	(3,501)
Net income for the period	8,364	5,161	9,644	15,725
Earnings per share:				
Basic	0.31	0.19	0.35	0.58
Diluted	0.30	0.19	0.35	0.57
=	0.30	0.19	0.33	0.57
Shares used for calculation of earnings per share:				
Basic	27,292	27,073	27,175	27,185
Diluted -	27,704	27,334	27,503	27,510
=	21,107	21,337	21,303	21,310

# NOVA MEASURING INSTRUMENTS LTD. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in thousands) - (Unaudited)

	Three months ended December 31,		Year ended December 31,	
	2016	2015	2016	2015
Cash flows from operating activities:	_			
Net income for the period	8,364	5,161	9,644	15,725
Adjustments to reconcile net income to net cash provided by (used in) operating activities:				
Depreciation	731	1,288	4,271	4,597
Amortization of acquired intangible assets	636	1,429	2,545	5,023
Amortization of deferred stock-based compensation Increase (decrease) in liability for employee	691	765	2,735	2,673
termination benefits, net	(57)	35	38	70
Deferred tax assets, net	2,028	(2,077)	633	(5,046)
Loss on securities	-	(23)	-	(10)
Decrease (increase) in trade accounts receivable	(19,068)	4,297	(23,580)	(1,959)
Decrease (increase) in inventories	(335)	745	(1,670)	(1,949)
Decrease (increase) in other current and long term				
assets	(1,885)	872	(2,180)	370
Increase in trade accounts payable	4,127	1,469	2,123	1,604
Increase in other current liabilities and				
other long-term liabilities	3,601	683	3,037	3,329
Increase (decrease) in short and long term deferred revenues	(351)	(1,928)	(1,756)	1,361
Net cash provided by (used in) operating activities	(1,518)	12,716	(4,160)	25,788
Cash flow from investment activities:				
Decrease (increase) in short-term interest-bearing				
bank deposits	(998)	(10,045)	(1,248)	37,991
Proceeds from short-term held for trading securities	_	2,005	-	2,005
Acquisition of subsidiary, net of acquired cash	_	-	-	(45,344)
Additions to property and equipment	(1,518)	(2,205)	(3,133)	(4,373)
Net cash used in investment activities	(2,516)	(10,245)	(4,381)	(9,721)
Cash flows from financing activities:				
Purchases of treasury shares	_	_	(937)	(4,302)
Shares issued under employee stock-based plans	786	232	2,151	2,319
r Just Family				-,,-
Net cash provided by (used in) financing activities	786	232	1,214	(1,983)
Increase (decrease) in cash and cash equivalents	(3,248)	2,703	(7,327)	14,084
Cash and cash equivalents – beginning of period	23,654	25,030	27,733	13,649
Cash and cash equivalents – beginning or period	20,406	27,733	20,406	27,733
Cash and cash equivalents – the or period	20,700	21,133	20,700	21,133

# NOVA MEASURING INSTRUMENTS LTD. RECONCILIATION OF GAAP TO NON-GAAP RESULTS (U.S. dollars in thousands, except percentage and per share data) - (Unaudited)

December 31, 2016   2		Three months ended		
Amortization of acquired intangible assets in cost of products   Capable		December 31,	September 30,	December 31,
Amortization of acquired intangible assets in cost of products  Expense related to royalty buyout agreement with the Office of the Chief Scientist  Office of the Chief Scientist  Inventory write-off  Stock-based compensation in cost of products  Stock-based compensation in cost of products  Stock-based compensation in cost of services  (54)  (52)  (63)  Non-GAAP cost of revenues  21,912  19,472  17,960  GAAP gross profit  28,158  9,693  20,854  Gross profit adjustments  142  14,895  1,208  RAP gross margin as a percentage of revenues  56%  Sow 56%  56%  GAAP gross margin as a percentage of revenues  56%  GAAP gross margin as a percentage of revenues  56%  GAAP gross margin as a percentage of revenues  56%  GAAP gross margin as a percentage of revenues  56%  GAAP operating expenses  17,377  16,640  17,284  Stock-based compensation in research and development  (247)  (200)  (322)  Stock-based compensation in general and administrative  (91)  (82)  (73)  Amortization of acquired intangible assets  (363)  (363)  (378)  Non-GAAP operating expenses  16,192  15,495  16,298  Non-GAAP operating margin as a percentage of revenues  21%  GAAP to perating margin as a percentage of revenues  22%  GAAP to perating margin as a percentage of revenues  24%  21%  GAAP operating margin as a percentage of revenues  24%  21%  GAAP operating margin as a percentage of revenues  24%  CHON-GAAP operating margin as a percentage of revenues  24%  CHON-GAAP operating margin as a percentage of revenues  24%  CHON-GAAP operating margin as a percentage of revenues  24%  CHON-GAAP operating margin as a percentage of revenues  CHON-GAAP operating margin as a percentage of revenues  24%  CHON-GAAP operating margin as a percentage of revenues  24%  CHON-GAAP operating margin as a percentage of revenues  24%  CHON-GAAP operating margin as a percentage of revenues  CHON-GAAP operating margin as a percentage of revenues  CHON-GAAP operating margin as a percentage of revenues  CHON-GAAP operating margin as operating operating operating operating oper		2016	2016	2015
Expense related to royalty buyout agreement with the Office of the Chief Scientist	GAAP cost of revenues	22,054	34,367	19,168
Expense related to royalty buyout agreement with the Office of the Chief Scientist	Amortization of acquired intangible assets in cost of			
Office of the Chief Scientist Inventory write-off         -         (12,875)         -           Inventory write-off         -         (1,889)         -           Stock-based compensation in cost of services         (54)         (52)         (63)           Non-GAAP cost of revenues         21,912         19,472         17,960           GAAP gross profit         28,158         9,693         20,854           Gross profit adjustments         142         14,895         1,208           Non-GAAP gross profit         28,300         24,588         22,062           GAAP gross margin as a percentage of revenues         56%         52%         52%           Non-GAAP gross margin as a percentage of revenues         56%         36%         22%         52%           GAAP operating expenses         17,377         16,640         17,284           Stock-based compensation in research and development         (247)         (200)         (322)           Stock-based compensation in sales and marketing         (211)         (226)         (213)           Stock-based compensation in sales and marketing         (211)         (226)         (213)           Stock-based compensation in selectant         (636)         (637)         (378)           Mon-GAAP operating income		-	-	(1,051)
Inventory write-off				
Stock-based compensation in cost of products   (88) (79) (94)   (52) (63)	Office of the Chief Scientist	-	(12,875)	-
Stock-based compensation in cost of services   21,912   19,472   17,960	•	-	(1,889)	-
Non-GAAP cost of revenues         21,912         19,472         17,960           GAAP gross profit adjustments         28,158         9,693         20,854           Gross profit adjustments         142         14,895         1,208           Non-GAAP gross profit gors profit         28,300         24,588         22,062           GAAP gross margin as a percentage of revenues         56%         22%         52%           Non-GAAP gross margin as a percentage of revenues         56%         56%         55%           GAAP operating expenses         17,377         16,640         17,284           Stock-based compensation in research and development         (247)         (200)         (322)           Stock-based compensation in general and administrative         (91)         (82)         (73)           Stock-based compensation in general and administrative         (91)         (82)         (73)           Amortization of acquired intangible assets         (636)         (637)         (378)           Non-GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         24%         21%         14%	Stock-based compensation in cost of products	(88)	(79)	(94)
GAAP gross profit dijustments	Stock-based compensation in cost of services	(54)	(52)	(63)
Gross profit adjustments         142         14,895         1,208           Non-GAAP gross profit         28,300         24,588         22,062           GAAP gross margin as a percentage of revenues         56%         22%         52%           Non-GAAP gross margin as a percentage of revenues         56%         56%         55%           GAAP operating expenses         17,377         16,640         17,284           Stock-based compensation in research and development         (247)         (200)         (322)           Stock-based compensation in sales and marketing stock-based compensation in general and administrative         (91)         (82)         (73)           Amortization of acquired intangible assets         (636)         (637)         (378)           Non-GAAP operating income         16,192         15,495         16,298           Non-GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating income         12,108         9,093         5,764           GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         21%         (16%)         9% <td>Non-GAAP cost of revenues</td> <td>21,912</td> <td>19,472</td> <td>17,960</td>	Non-GAAP cost of revenues	21,912	19,472	17,960
Gross profit adjustments         142         14,895         1,208           Non-GAAP gross profit         28,300         24,588         22,062           GAAP gross margin as a percentage of revenues         56%         22%         52%           Non-GAAP gross margin as a percentage of revenues         56%         56%         55%           GAAP operating expenses         17,377         16,640         17,284           Stock-based compensation in research and development         (247)         (200)         (322)           Stock-based compensation in sales and marketing stock-based compensation in general and administrative         (91)         (82)         (73)           Amortization of acquired intangible assets         (636)         (637)         (378)           Non-GAAP operating income         16,192         15,495         16,298           Non-GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating income         12,108         9,093         5,764           GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         21%         (16%)         9% <td>CAAD areas mustit</td> <td>20 150</td> <td>0.602</td> <td>20.954</td>	CAAD areas mustit	20 150	0.602	20.954
Non-GAAP gross profit         28,300         24,588         22,062           GAAP gross margin as a percentage of revenues         56%         22%         52%           Non-GAAP gross margin as a percentage of revenues         56%         56%         55%           GAAP operating expenses         17,377         16,640         17,284           Stock-based compensation in research and development         (247)         (200)         (322)           Stock-based compensation in general and administrative         (91)         (82)         (73)           More GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         21%         (16%)         9%           GAAP ax on income         2,607         (1,868)         (1,407)           Deferred tax assets adjustments, net         (2,028)         1,813         2,077           Non-GAAP tax on income         579         (55)         670           GAAP net income (loss)<		· ·	· ·	
GAAP gross margin as a percentage of revenues         56%         22%         52%           Non-GAAP gross margin as a percentage of revenues         56%         56%         55%           GAAP operating expenses         17,377         16,640         17,284           Stock-based compensation in research and development         (247)         (200)         (322)           Stock-based compensation in general and administrative         (91)         (82)         (73)           Amortization of acquired intangible assets         (636)         (637)         (378)           Non-GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating income         12,108         9,093         5,764           GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP operating margin as a percentage of revenues         2607         (1,868)         (1,407)           Deferred tax assets adjustments, net         (2,028)         1,813         2,077           Non-GAAP tax on income         579         (55)         670      <				
Non-GAAP gross margin as a percentage of revenues         56%         55%           GAAP operating expenses         17,377         16,640         17,284           Stock-based compensation in research and development         (247)         (200)         (322)           Stock-based compensation in sales and marketing administrative         (211)         (226)         (213)           Stock-based compensation in general and administrative         (91)         (82)         (73)           Amortization of acquired intangible assets         (636)         (637)         (378)           Non-GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating income         12,108         9,093         5,764           GAAP operating margin as a percentage of revenues         21%         (10%)         9%           Non-GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP aperating margin as a percentage of revenues         2607         (1,868)				
GAAP operating expenses         17,377         16,640         17,284           Stock-based compensation in research and development         (247)         (200)         (322)           Stock-based compensation in sales and marketing         (211)         (226)         (213)           Stock-based compensation in general and administrative         (91)         (82)         (73)           Amortization of acquired intangible assets         (636)         (637)         (378)           Non-GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating income         12,108         9,093         5,764           GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP tax on income         2,607         (1,868)         (1,407)           Deferred tax assets adjustments, net         (2,028)         1,813         2,077 <t< td=""><td></td><td></td><td></td><td></td></t<>				
Stock-based compensation in research and development (247) (200) (322)         (322)           Stock-based compensation in sales and marketing (211) (226) (213)         (213)           Stock-based compensation in general and administrative (91) (82) (73)         (378)           Amortization of acquired intangible assets (636) (637) (378)         (366) (637) (378)           Non-GAAP operating expenses (16,192) (15,495) (16,298)         (16,298)           Non-GAAP operating income (12,108) (16%)	Non-GAAP gross margin as a percentage of revenues	56%	56%	55%
Stock-based compensation in research and development (247) (200) (322)         (322)           Stock-based compensation in sales and marketing (211) (226) (213)         (213)           Stock-based compensation in general and administrative (91) (82) (73)         (378)           Amortization of acquired intangible assets (636) (637) (378)         (366) (637) (378)           Non-GAAP operating expenses (16,192) (15,495) (16,298)         (16,298)           Non-GAAP operating income (12,108) (16%)	GAAP operating expenses	17,377	16,640	17,284
development         (247)         (200)         (322)           Stock-based compensation in sales and marketing         (211)         (226)         (213)           Stock-based compensation in general and administrative         (91)         (82)         (73)           Amortization of acquired intangible assets         (636)         (637)         (378)           Non-GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating income         12,108         9,093         5,764           GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP not income         2,607         (1,868)         (1,407)           Deferred tax assets adjustments, net         (2,028)         1,813         2,077           Non-GAAP tax on income         579         (55)         670           GAAP net income (loss)         8,364         (4,778)         5,161           Amortization of acquired intangible assets         636         637         1,429           Expense related to royalty buyout agreement with the Office of the Chief Scientist         -         12,875         -           Stock-based compensation expen		•	·	•
Stock-based compensation in sales and marketing         (211)         (226)         (213)           Stock-based compensation in general and administrative         (91)         (82)         (73)           Amortization of acquired intangible assets         (636)         (637)         (378)           Non-GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating income         12,108         9,093         5,764           GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP tax on income         2,607         (1,868)         (1,407)           Deferred tax assets adjustments, net         (2,028)         1,813         2,077           Non-GAAP tax on income         579         (55)         670           GAAP net income (loss)         8,364         (4,778)         5,161           Amortization of acquired intangible assets         636         637         1,429           Expense related to royalty buyout agreement with the Office of the Chief Scientist         -         12,875         -           Stock-based compensation expenses         691         639         765           Deferred ta		(247)	(200)	(322)
Stock-based compensation in general and administrative	*	, ,	` '	, ,
administrative         (91)         (82)         (73)           Amortization of acquired intangible assets         (636)         (637)         (378)           Non-GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating income         12,108         9,093         5,764           GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP tax on income         2,607         (1,868)         (1,407)           Deferred tax assets adjustments, net         (2,028)         1,813         2,077           Non-GAAP tax on income         579         (55)         670           GAAP net income (loss)         8,364         (4,778)         5,161           Amortization of acquired intangible assets         636         637         1,429           Expense related to royalty buyout agreement with the Office of the Chief Scientist         -         12,875         -           Stock-based compensation expenses         691         639         765         5           Deferred tax assets adjustments, net         2,028         (1,813)         (2,077)           Inventory write-off         -<		` ,	, ,	` ,
Amortization of acquired intangible assets  Non-GAAP operating expenses  Non-GAAP operating income  12,108  12,108  9,093  5,764  GAAP operating margin as a percentage of revenues  Non-GAAP operating margin as a percentage of revenues  Non-GAAP operating margin as a percentage of revenues  24%  11%  GAAP tax on income  2,607  CAAP tax on income  2,607  CAAP tax on income  2,028  1,813  2,077  Non-GAAP tax on income  3,364  4,4778  5,161  Amortization of acquired intangible assets  Expense related to royalty buyout agreement with the Office of the Chief Scientist  CHief Scientist  - 12,875  Stock-based compensation expenses  691  CASP  Deferred tax assets adjustments, net  2,028  1,813  2,077  1,429  Expense related to royalty buyout agreement with the Office of the Chief Scientist  - 12,875  - 5  Stock-based compensation expenses  691  CASP  Deferred tax assets adjustments, net  2,028  1,813  2,077  Inventory write-off  - 1,889  - Non-GAAP net income  11,719  9,449  5,278  GAAP basic earnings (loss) per share  0,31  CASP  O,18  O,19  Non-GAAP diluted earnings (loss) per share  0,43  0,35  0,19  Shares used for calculation of earnings (loss) per share:  Basic  27,292  27,169  27,073		(91)	(82)	(73)
Non-GAAP operating expenses         16,192         15,495         16,298           Non-GAAP operating income         12,108         9,093         5,764           GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP tax on income         2,607         (1,868)         (1,407)           Deferred tax assets adjustments, net         (2,028)         1,813         2,077           Non-GAAP tax on income         579         (55)         670           GAAP net income (loss)         8,364         (4,778)         5,161           Amortization of acquired intangible assets         636         637         1,429           Expense related to royalty buyout agreement with the Office of the Chief Scientist         -         -         12,875         -           Stock-based compensation expenses         691         639         765         5           Deferred tax assets adjustments, net         2,028         (1,813)         (2,077)           Inventory write-off         -         1,889         -           Non-GAAP net income         11,719         9,449         5,278           GAAP basic earnings (loss) per share		, ,	* *	` '
Non-GAAP operating income         12,108         9,093         5,764           GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP tax on income         2,607         (1,868)         (1,407)           Deferred tax assets adjustments, net         (2,028)         1,813         2,077           Non-GAAP tax on income         579         (55)         670           GAAP net income (loss)         8,364         (4,778)         5,161           Amortization of acquired intangible assets         636         637         1,429           Expense related to royalty buyout agreement with the Office of the Chief Scientist         -         12,875         -           Stock-based compensation expenses         691         639         765           Deferred tax assets adjustments, net         2,028         (1,813)         (2,077)           Inventory write-off         -         1,889         -           Non-GAAP net income         11,719         9,449         5,278           GAAP basic earnings (loss) per share         0.31         (0.18)         0.19           Non-GAAP diluted earnings per share         0.42	<del>_</del>	` /		
GAAP operating margin as a percentage of revenues         21%         (16%)         9%           Non-GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP tax on income         2,607         (1,868)         (1,407)           Deferred tax assets adjustments, net         (2,028)         1,813         2,077           Non-GAAP tax on income         579         (55)         670           GAAP net income (loss)         8,364         (4,778)         5,161           Amortization of acquired intangible assets         636         637         1,429           Expense related to royalty buyout agreement with the Office of the Chief Scientist         -         12,875         -           Stock-based compensation expenses         691         639         765           Deferred tax assets adjustments, net         2,028         (1,813)         (2,077)           Inventory write-off         -         1,889         -           Non-GAAP net income         11,719         9,449         5,278           GAAP basic earnings (loss) per share         0.31         (0.18)         0.19           Non-GAAP diluted earnings per share         0.30         (0.18)         0.19           Shares used for calculation of earnings (loss) per share:	1 0 1			
Non-GAAP operating margin as a percentage of revenues         24%         21%         14%           GAAP tax on income         2,607         (1,868)         (1,407)           Deferred tax assets adjustments, net         (2,028)         1,813         2,077           Non-GAAP tax on income         579         (55)         670           GAAP net income (loss)         8,364         (4,778)         5,161           Amortization of acquired intangible assets         636         637         1,429           Expense related to royalty buyout agreement with the Office of the Chief Scientist         -         12,875         -           Stock-based compensation expenses         691         639         765         765           Deferred tax assets adjustments, net         2,028         (1,813)         (2,077)           Inventory write-off         -         1,889         -           Non-GAAP net income         11,719         9,449         5,278           GAAP basic earnings (loss) per share         0.31         (0.18)         0.19           Non-GAAP diluted earnings (loss) per share         0.30         (0.18)         0.19           Shares used for calculation of earnings (loss) per share:         27,292         27,169         27,073				
Deferred tax assets adjustments, net         (2,028)         1,813         2,077           Non-GAAP tax on income         579         (55)         670           GAAP net income (loss)         8,364         (4,778)         5,161           Amortization of acquired intangible assets         636         637         1,429           Expense related to royalty buyout agreement with the Office of the Chief Scientist         -         12,875         -           Stock-based compensation expenses         691         639         765           Deferred tax assets adjustments, net         2,028         (1,813)         (2,077)           Inventory write-off         -         1,889         -           Non-GAAP net income         11,719         9,449         5,278           GAAP basic earnings (loss) per share         0.31         (0.18)         0.19           Non-GAAP diluted earnings (loss) per share         0.43         0.35         0.19           GAAP diluted earnings per share         0.42         0.34         0.19           Shares used for calculation of earnings (loss) per share:         27,292         27,169         27,073			, , ,	
Deferred tax assets adjustments, net         (2,028)         1,813         2,077           Non-GAAP tax on income         579         (55)         670           GAAP net income (loss)         8,364         (4,778)         5,161           Amortization of acquired intangible assets         636         637         1,429           Expense related to royalty buyout agreement with the Office of the Chief Scientist         -         12,875         -           Stock-based compensation expenses         691         639         765           Deferred tax assets adjustments, net         2,028         (1,813)         (2,077)           Inventory write-off         -         1,889         -           Non-GAAP net income         11,719         9,449         5,278           GAAP basic earnings (loss) per share         0.31         (0.18)         0.19           Non-GAAP diluted earnings (loss) per share         0.43         0.35         0.19           GAAP diluted earnings per share         0.42         0.34         0.19           Shares used for calculation of earnings (loss) per share:         27,292         27,169         27,073	GAAP tay on income	2 607	(1 969)	(1.407)
Non-GAAP tax on income         579         (55)         670           GAAP net income (loss)         8,364         (4,778)         5,161           Amortization of acquired intangible assets         636         637         1,429           Expense related to royalty buyout agreement with the Office of the Chief Scientist         -         12,875         -           Stock-based compensation expenses         691         639         765           Deferred tax assets adjustments, net         2,028         (1,813)         (2,077)           Inventory write-off         -         1,889         -           Non-GAAP net income         11,719         9,449         5,278           GAAP basic earnings (loss) per share         0.31         (0.18)         0.19           Non-GAAP diluted earnings (loss) per share         0.30         (0.18)         0.19           GAAP diluted earnings per share         0.42         0.34         0.19           Shares used for calculation of earnings (loss) per share:         27,292         27,169         27,073		•	* * *	
GAAP net income (loss)       8,364       (4,778)       5,161         Amortization of acquired intangible assets       636       637       1,429         Expense related to royalty buyout agreement with the Office of the Chief Scientist       -       12,875       -         Stock-based compensation expenses       691       639       765         Deferred tax assets adjustments, net       2,028       (1,813)       (2,077)         Inventory write-off       -       1,889       -         Non-GAAP net income       11,719       9,449       5,278         GAAP basic earnings (loss) per share       0.31       (0.18)       0.19         Non-GAAP diluted earnings (loss) per share       0.43       0.35       0.19         GAAP diluted earnings per share       0.30       (0.18)       0.19         Shares used for calculation of earnings (loss) per share:       0.42       0.34       0.19         Shares used for calculation of earnings (loss) per share:       27,292       27,169       27,073				
Amortization of acquired intangible assets       636       637       1,429         Expense related to royalty buyout agreement with the Office of the Chief Scientist       -       12,875       -         Stock-based compensation expenses       691       639       765         Deferred tax assets adjustments, net       2,028       (1,813)       (2,077)         Inventory write-off       -       1,889       -         Non-GAAP net income       11,719       9,449       5,278         GAAP basic earnings (loss) per share       0.31       (0.18)       0.19         Non-GAAP basic earnings per share       0.43       0.35       0.19         GAAP diluted earnings (loss) per share       0.30       (0.18)       0.19         Shares used for calculation of earnings (loss) per share:       0.42       0.34       0.19         Shares used for calculation of earnings (loss) per share:       27,292       27,169       27,073	Non-GAAP tax on income	319	(55)	670
Expense related to royalty buyout agreement with the Office of the Chief Scientist       -       12,875       -         Stock-based compensation expenses       691       639       765         Deferred tax assets adjustments, net       2,028       (1,813)       (2,077)         Inventory write-off       -       1,889       -         Non-GAAP net income       11,719       9,449       5,278         GAAP basic earnings (loss) per share       0.31       (0.18)       0.19         Non-GAAP basic earnings per share       0.43       0.35       0.19         GAAP diluted earnings (loss) per share       0.30       (0.18)       0.19         Shares used for calculation of earnings (loss) per share:       0.42       0.34       0.19         Shares used for calculation of earnings (loss) per share:       27,292       27,169       27,073	GAAP net income (loss)	8,364	(4,778)	5,161
Office of the Chief Scientist         -         12,875         -           Stock-based compensation expenses         691         639         765           Deferred tax assets adjustments, net         2,028         (1,813)         (2,077)           Inventory write-off         -         1,889         -           Non-GAAP net income         11,719         9,449         5,278           GAAP basic earnings (loss) per share         0.31         (0.18)         0.19           Non-GAAP basic earnings per share         0.43         0.35         0.19           GAAP diluted earnings (loss) per share         0.30         (0.18)         0.19           Non-GAAP diluted earnings per share         0.42         0.34         0.19           Shares used for calculation of earnings (loss) per share:         27,292         27,169         27,073	Amortization of acquired intangible assets	636	637	1,429
Stock-based compensation expenses       691       639       765         Deferred tax assets adjustments, net       2,028       (1,813)       (2,077)         Inventory write-off       -       1,889       -         Non-GAAP net income       11,719       9,449       5,278         GAAP basic earnings (loss) per share       0.31       (0.18)       0.19         Non-GAAP basic earnings per share       0.43       0.35       0.19         GAAP diluted earnings (loss) per share       0.30       (0.18)       0.19         Non-GAAP diluted earnings per share       0.42       0.34       0.19         Shares used for calculation of earnings (loss) per share:       27,292       27,169       27,073	Expense related to royalty buyout agreement with the			
Deferred tax assets adjustments, net       2,028       (1,813)       (2,077)         Inventory write-off       -       1,889       -         Non-GAAP net income       11,719       9,449       5,278         GAAP basic earnings (loss) per share       0.31       (0.18)       0.19         Non-GAAP basic earnings per share       0.43       0.35       0.19         GAAP diluted earnings (loss) per share       0.30       (0.18)       0.19         Non-GAAP diluted earnings per share       0.42       0.34       0.19         Shares used for calculation of earnings (loss) per share:       27,292       27,169       27,073	Office of the Chief Scientist	-	12,875	-
Inventory write-off         -         1,889         -           Non-GAAP net income         11,719         9,449         5,278           GAAP basic earnings (loss) per share         0.31         (0.18)         0.19           Non-GAAP basic earnings per share         0.43         0.35         0.19           GAAP diluted earnings (loss) per share         0.30         (0.18)         0.19           Non-GAAP diluted earnings per share         0.42         0.34         0.19           Shares used for calculation of earnings (loss) per share:         27,292         27,169         27,073	Stock-based compensation expenses	691	639	765
Non-GAAP net income         11,719         9,449         5,278           GAAP basic earnings (loss) per share         0.31         (0.18)         0.19           Non-GAAP basic earnings per share         0.43         0.35         0.19           GAAP diluted earnings (loss) per share         0.30         (0.18)         0.19           Non-GAAP diluted earnings per share         0.42         0.34         0.19           Shares used for calculation of earnings (loss) per share:         27,292         27,169         27,073	Deferred tax assets adjustments, net	2,028	(1,813)	(2,077)
GAAP basic earnings (loss) per share         0.31         (0.18)         0.19           Non-GAAP basic earnings per share         0.43         0.35         0.19           GAAP diluted earnings (loss) per share         0.30         (0.18)         0.19           Non-GAAP diluted earnings per share         0.42         0.34         0.19           Shares used for calculation of earnings (loss) per share:         27,292         27,169         27,073	Inventory write-off	-	1,889	
Non-GAAP basic earnings per share  O.43  O.35  O.19  GAAP diluted earnings (loss) per share  O.30  Non-GAAP diluted earnings per share  O.42  O.34  O.19  Shares used for calculation of earnings (loss) per share:  Basic  D.42  D.42  D.49  27,073	Non-GAAP net income	11,719	9,449	5,278
Non-GAAP basic earnings per share  O.43  O.35  O.19  GAAP diluted earnings (loss) per share  O.30  Non-GAAP diluted earnings per share  O.42  O.34  O.19  Shares used for calculation of earnings (loss) per share:  Basic  D.42  D.42  D.49  27,073	GAAP basic carnings (loss) per chera	0.21	(0.19)	0.10
GAAP diluted earnings (loss) per share  Non-GAAP diluted earnings per share  0.30 (0.18) 0.19  0.42 0.34 0.19  Shares used for calculation of earnings (loss) per share:  Basic 27,292 27,169 27,073				
Non-GAAP diluted earnings per share 0.42 0.34 0.19  Shares used for calculation of earnings (loss) per share: Basic 27,292 27,169 27,073	Non-GAAP basic earnings per snare	0.43	0.35	0.19
Non-GAAP diluted earnings per share 0.42 0.34 0.19  Shares used for calculation of earnings (loss) per share: Basic 27,292 27,169 27,073	GAAP diluted earnings (loss) per share	0.30	(0.18)	0.19
Basic <u>27,292</u> <u>27,169</u> <u>27,073</u>				
Basic <u>27,292</u> <u>27,169</u> <u>27,073</u>	Change wood for coloration of some (4.1)			
	— — — — — — — — — — — — — — — — — — —	27.202	27.170	27.072
Diluted <u>27,704</u> <u>27,536</u> <u>27,334</u>				
	Diluted	27,704	27,536	27,334

# NOVA MEASURING INSTRUMENTS LTD. RECONCILIATION OF GAAP TO NON-GAAP RESULTS (U.S. dollars in thousands, except percentage and per share data) - (Unaudited)

	Year ended December 31,	
_	2016	2015
GAAP cost of revenues	88,623	71,434
Amortization of acquired intangible assets in cost of products Expense related to royalty buyout agreement with the Office of the	-	(3,506)
Chief Scientist	(12,875)	-
Inventory write-off	(1,889)	-
Stock-based compensation in cost of products	(342)	(373)
Stock-based compensation in cost of services	(218)	(203)
Non-GAAP cost of revenues	73,299	67,352
GAAP gross profit	75,280	77,080
Gross profit adjustments	15,324	4,082
Non-GAAP gross profit	90,604	81,162
GAAP gross margin as a percentage of revenues	46%	52%
Non-GAAP gross margin as a percentage of revenues	55%	55%
GAAP operating expenses	65,114	65,499
Stock-based compensation in research and development	(983)	(1,084)
Stock-based compensation in sales and marketing	(884)	(744)
Stock-based compensation in general and administrative	(308)	(269)
Acquisition related expenses	-	(2,655)
Amortization of acquired intangible assets	(2,545)	(1,517)
Non-GAAP operating expenses	60,394	59,230
Non-GAAP operating income	30,210	21,932
GAAP operating margin as a percentage of revenues Non-GAAP operating margin as a percentage of revenues	6% 18%	8% 15%
GAAP tax on income	1,738	(3,501)
Deferred tax assets adjustments, net	(633)	5,046
Non-GAAP tax on income	1,105	1,545
GAAP net income	9,644	15,725
Amortization of acquired intangible assets	2,545	5,023
Expense related to royalty buyout agreement with the Office of the		
Chief Scientist	12,875	-
Stock-based compensation expenses	2,735	2,673
Deferred tax assets adjustments, net	633	(5,046)
Inventory write-off Acquisition related expenses	1,889	2,655
Non-GAAP net income	30,321	21,030
CAAD basis saminas nan shara	0.25	
GAAP basic earnings per share	0.35	0.58
Non-GAAP basic earnings per share	1.12	0.77
GAAP diluted earnings per share	0.35	0.57
Non-GAAP diluted earnings per share	1.10	0.76
Shares used for calculation of earnings per share:		
Basic	27,175	27,185
Diluted	27,503	27,510